Sunshine Biopharma (SBFM) Capital Expenditures Growth (1y) (2016 - 2026)
Sunshine Biopharma (SBFM) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -21.54% |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | -31.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.52% |
| Dec 31, 2025 | -101.01% |
| Sep 30, 2025 | -98.44% |
| Jun 30, 2025 | -83.58% |
| Mar 31, 2025 | -88.10% |
| Dec 31, 2024 | 126.83% |
| Sep 30, 2024 | 5,266.46% |
| Dec 31, 2023 | -297.11% |
| Dec 31, 2020 | -54.53% |
| Sep 30, 2020 | 264.95% |
| Dec 31, 2019 | 110.09% |
| Sep 30, 2019 | -109.70% |
| Jun 30, 2019 | -97.24% |
| Dec 31, 2018 | -329.16% |
| Sep 30, 2018 | 122.43% |
| Jun 30, 2018 | -21.12% |
| Dec 31, 2017 | 239.23% |
| Jun 30, 2017 | 851.56% |
| Dec 31, 2016 | -77.13% |